Skip to main content
Clinical Trials/NCT01667809
NCT01667809
Completed
Phase 3

Cognitive Behavior Therapy Versus a Return to Work Intervention for Sick-listed Patients With Subclinical Common Mental Illness in Primary Care: a Randomized Controlled Trial

Karolinska Institutet1 site in 1 country5 target enrollmentAugust 2012

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Anxiety Disorders
Sponsor
Karolinska Institutet
Enrollment
5
Locations
1
Primary Endpoint
Clinician Severity Rating (CSR)
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Background: Common mental illness, such as anxiety disorders and depression, is the main cause for sick leave in Sweden. Cognitive behavior therapy (CBT) has been shown to be effective in alleviating target symptoms of these disorders, but its effect on sick leave rates has not been sufficiently addressed. The investigators have developed an intervention called return to work (RTW), which is based in cognitive behavioral theory, that has a primary aim of helping sick-listed patients with common mental illness return to work. This new treatment has not been evaluated in a randomized controlled trial.

Aims: The aim of this study is to investigate the effect of CBT and RTW for subclinical common mental illness in a randomized controlled trial conducted in primary care. Participants will be randomized to diagnosis specific CBT (n=50), RTW (n=50. Main outcomes are days of sick leave and clinician severity rating of psychiatric symptoms. This study could contribute to new knowledge regarding how to best treat patients on sick leave with mild common mental illness.

Registry
clinicaltrials.gov
Start Date
August 2012
End Date
December 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Erik Hedman

Principal investigator

Karolinska Institutet

Eligibility Criteria

Inclusion Criteria

  • Have been on sick leave (at least 50%) for at least 1 month and not more than 6 months
  • Have subclinical levels of anxiety disorder diagnosis (obsessive compulsive disorder, social phobia, panic disorder, generalized anxiety disorder, post-traumatic stress disorder, specific phobia), or/and major depression, or/and maladaptive stress reaction, or/and primary insomnia. Severity measured by clinical severity rating (CSR) 2-3 for mild subclinical level

Exclusion Criteria

  • A higer score than 3 on the Clinician severity rating scale
  • A lower score than 2 on the Clinician severity rating scale

Outcomes

Primary Outcomes

Clinician Severity Rating (CSR)

Time Frame: Baseine, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up

Change in CSR at post-treatment, 26 week follow-up, and 52 week follow-up compared to baseline.

Sick leave

Time Frame: 1 year

Number of days on sick leave

Secondary Outcomes

  • EuroQol-5 dimension (EQ5D)(Baseline, post-treatment (12 weeks on average) 26 feel follow-up, 52 week follow-up)
  • Panic Disorder Severity Scale Self-rated (PDSS-SR)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)
  • Insomnia Severity Index (ISI)(Baseline, post-treatment (12 weeks on average) 26 week follow-up, 52 week follow-up)
  • Perceived Stress Scale (PSS)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)
  • Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)
  • Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)
  • Health Anxiety Inventory (HAI)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)
  • Quality of Life Inventory (QOLI)(Baseline, post-treatment (12 weeks on average) 26 week follow-up, 52 week follow-up)
  • Obsessive Compulsive Inventory-Revised (OCI-R)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)
  • Liebowitz Social Anxiety Scale Self-report (LSAS-SR)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)
  • Sheehan Disability Scales (SDS)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)
  • Self-rated health 5 (SRH-5)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)
  • Post Traumatic Stress Disorder Symptom Scale-Self report (PTSDSS)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)
  • Penn-State Worry Questionnaire (PSWQ)(Baseline, post-treatment (12 weeks on average), 26 week follow-up, 52 week follow-up)

Study Sites (1)

Loading locations...

Similar Trials